Carfilzomib API

Name	Carfilzomib
Chinese name	卡非佐米
Cas Number	868540-17-4
Source	India
Qualifications	USDMF/-/-/-/-

The original research is Amgen, and it was approved by the FDA in July 2012. It belongs to the proteasome inhibitor (PI) together with bortezomib for the treatment of relapsed/refractory multiple myeloma (MM). Compared with bortezomib, carfilzomib has stronger proteasome inhibitory activity and fewer off-target effects. As a new generation of highly selective irreversible proteasome blocking drugs, multiple clinical studies have confirmed that carfilzomib alone or in combination with other drugs has a strong anti-MM effect with little toxicity, especially the incidence of peripheral neuropathy. Low, good patient tolerance, high safety, and long-term clinical use. The industry predicts that it may replace bortezomib, and the market prospects are promising.

Hot Tags: carfilzomib api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Bivalrudine API, Lifitegrast API, Brinzolamide API, Troxagliptin Succinate API, Ticagrelor API, Lurasidone Hydrochloride API

• Previous: Mesna API
• Next: Latanoprost API